https://scholars.lib.ntu.edu.tw/handle/123456789/307513
標題: | Small molecules targeting severe acute respiratory syndrome human coronavirus | 作者: | Wu, C.-Y. HSUEH-FEN JUAN JIM-MIN FANGet al. |
公開日期: | 七月-2004 | 卷: | 101 | 期: | 27 | 起(迄)頁: | 10012-10017 | 來源出版物: | Proceedings of the National Academy of Sciences of the United States of America | 摘要: | Severe acute respiratory syndrome (SARS) is an infectious disease caused by a novel human coronavirus. Currently, no effective antiviral agents exist against this type of virus. A cell-based assay, with SARS virus and Vero E6 cells, was developed to screen existing drugs, natural products, and synthetic compounds to identify effective anti-SARS agents. Of >10,000 agents tested, ?50 compounds were found active at 10 μM; among these compounds, two are existing drugs (Reserpine 13 and Aescin 5) and several are in clinical development. These 50 active compounds were tested again, and compounds 2-6, 10, and 13 showed active at 3 μM. The 50% inhibitory concentrations for the inhibition of viral replication (EC50) and host growth (CC 50) were then measured and the selectivity index (SI = CC 50/EC50) was determined. The EC50, based on ELISA, and SI for Reserpine, Aescim, and Valinomycin are 3.4 μM (SI = 7.3), 6.0 μM (SI = 2.5), and 0.85 μM (SI = 80), respectively. Additional studies were carried out to further understand the mode of action of some active compounds, including ELISA, Western blot analysis, immunofluorescence and flow cytometry assays, and inhibition against the 3CL protease and viral entry. Of particular interest are the two anti-HIV agents, one as an entry blocker and the other as a 3CL protease inhibitor (Ki = 0.6 μM). |
URI: | http://europepmc.org/abstract/med/15226499 http://scholars.lib.ntu.edu.tw/handle/123456789/307513 |
DOI: | 10.1073/pnas.0403596101 | SDG/關鍵字: | alpha hederin; anti human immunodeficiency virus agent; antivirus agent; ascorbic acid; didanosine; escin; fp 21399; ginsenoside Rb 1; glycyrrhizic acid; iminocyclitol; lopinavir; lopinavir plus ritonavir; macrolide; melatonin; natural product; nevirapine; pentoxifylline; proteinase inhibitor; reserpine; ribavirin; ritonavir; rupintrivir; saponin; saquinavir; unclassified drug; valinomycin; zidovudine; animal cell; article; controlled study; drug screening; enzyme linked immunosorbent assay; flow cytometry; immunofluorescence; nonhuman; priority journal; SARS coronavirus; severe acute respiratory syndrome; virus cell interaction; virus replication; Western blotting; Animals; Antiviral Agents; Blotting, Western; Cercopithecus aethiops; Cysteine Endopeptidases; Endopeptidases; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Antibody Technique; SARS Virus; Vero Cells; Viral Proteins; Virus Replication; Animalia; Coronavirus; Human immunodeficiency virus; RNA viruses; SARS coronavirus |
顯示於: | 生命科學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。